Table 1 PDLSVT subject profiles. Levodopa equivalent values (LED) values represent the milligram dosage in each medication consumption
From: Quantitative clinical assessment of motor function during and following LSVT-BIG® therapy
Subject No. | Age | Gender | Height | Weight | BMI | Time Since Diagnosis | Side Most Affected | LED | HY | MDS-UPDRS Total | MDS-UPDRS Motor | PDQ39 | ACE III | PAS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
[#] | [yrs] | [m] | [Kg] | [Kg/m2] | [yrs] | [mg] | (Baseline) | (Baseline) | (Baseline) | (Baseline) | (Baseline) | (Baseline) | ||
1 | 78 | M | 1.72 | 80 | 26.98 | 0.5 | Right | 1003 | 3 | 58 | 37 | 27.56% | 79% | 8.33% |
2 | 74 | M | 1.85 | 123.4 | 35.89 | 3.0 | Left | 1003 | 3 | 78 | 42 | 12.18% | 94% | 8.33% |
3 | 66 | M | 1.75 | 76 | 24.74 | 8.0 | Right | 1504 | 2.5 | 67 | 33 | 26.92% | 94% | 27.08% |
4 | 76 | F | 1.65 | 70.1 | 25.72 | 3.2 | Right | 1003 | 3 | 40 | 23 | 25.00% | 96% | 16.66% |
5 | 67 | M | 1.73 | 72.8 | 24.25 | 2.0 | Right | 1003 | 2 | 29 | 9 | 21.15% | 88% | 20.83% |
6 | 86 | M | 1.70 | 79.1 | 27.52 | 0.4 | Right | 62.52 | 1.5 | 16 | 11 | 12.82% | 88% | 6.25% |
7 | 72 | F | 1.55 | 67.7 | 28.20 | 0.3 | Right | 12.53 | 1 | 9 | 5 | 11.54% | 88% | 18.75% |
8 | 72 | M | 1.82 | 80.9 | 24.36 | 10.0 | Left | 1004, 200N | 1.5 | 41 | 21 | 22.44% | 83% | 4.12% |
9 | 75 | F | 1.57 | 66.2 | 26.69 | 0.4 | Right | 62.53 | 2.5 | 49 | 32 | 12.17% | 78% | 8.33% |
10 | 84 | M | 1.80 | 68.5 | 21.06 | 4.0 | Left | 2602* | 2.5 | 38 | 30 | 0.00% | 87% | 0.00% |
11 | 72 | M | 1.73 | 74.8 | 25.07 | 3.0 | Right | 0 | 2.5 | 65 | 36 | 21.13% | 87% | 41.66% |
12 | 75 | M | 1.71 | 109.4 | 37.49 | 0.7 | Left | 1503 | 1.5 | 35 | 18 | 10.26% | 90% | 25.00% |
Mean | 74.75 | 1.72 | 80.74 | 27.33 | 2.96 | 2.21 | 43.75 | 24.75 | 16.93% | 87.67% | 15.45% | |||
(SD) | 5.91 | 0.09 | 17.61 | 4.77 | 3.14 | 0.69 | 20.72 | 12.11 | 0.08 | 0.06 | 0.12 |